IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.

Trial Details

NCT ID
NCT06119685
Phase
PHASE1 / PHASE2
Sponsor
Indapta Therapeutics, INC.
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • IDP-023
  • Rituximab
  • Daratumumab
  • Interleukin-2
  • Cyclophosphamide
  • Fludarabine
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Lake Mary, Florida, United States|28.75888,-81.31784
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Minneapolis, Minnesota, United States|44.97997,-93.26384
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and/or refractory (R/R) disease after ≥ 3 prior lines of therapy.
  • For NHL patients: R/R disease and failed ≥ 2 lines of systemic chemotherapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of greater than 12 weeks per the Investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →